These drugs can inhibit the production of many inflammatory mediators such as tumour necrosis factor-alpha (TNF-α), IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, and interferon-γ (IFN-γ), inhibiting the secretion of beta fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF)9,10, showing pleiotropic effects on MM cells and their microenvironment, promoting cell apoptosis, interfering with the production of cell adhesion factors, regulating the production of cytokines and inhibiting the production of tumour related angiogenesis.11–13. The gene discussed is VEGFA; the disease is Miyoshi myopathy.